About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Strategic Alliances
  > ABOUT US
  Overview
  Businesses
  Key Facts
  Vision Mission Values
  People
  Quality
  CSR Policy
  EHS Policy
  History
  Awards
  Biocon in Malaysia
  
  
     
 

Strategic Alliance


BIOCON – BRISTOL-MYERS SQUIBB: 2012

Biocon entered into an option agreement with Bristol-Myers Squibb for Biocon's IN-105, an oral insulin drug candidate

Biocon to continue development of IN-105 through Phase II; Bristol-Myers Squibb will have an exclusive option to further develop and commercialize IN-105, pending outcome of clinical trials.

Under the terms of the agreement, Bristol-Myers Squibb will have the right to exercise an option to obtain an exclusive worldwide license to the program. Biocon will conduct clinical studies to further characterize IN-105's clinical profile according to a pre-agreed development program up to the completion of Phase II.

If Bristol-Myers Squibb exercises its option to license IN-105 following the successful completion of the Phase II trial, Bristol-Myers Squibb will assume full responsibility for the development program, including all development and commercialization activities outside India. Biocon will receive a license fee in addition to potential regulatory and commercial milestone payments and royalties on commercial sales of IN-105 outside India. Biocon will retain exclusive rights to IN-105 in India.




 
 
Business Alliance
 
 
 
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved